Aim of the studyVascular endothelial growth factor (VEGF) is one of the parameters that has been studied in differential diagnosis of malignant fluids. This study is aimed at evaluate applicability of serum, fluid VEGF level and fluid to serum VEGF ratio in the diagnosis of malignant pleural mesothelioma (MPM).Material and methodsThe patients with pleural effusion over age of 18, between 2011 and 2015 were included in the study. They were divided into three groups: group 1 – mesothelioma patients; group 2 – other malignancies; and group 3 – benign aetiologies. Group 1 and 2 were termed as the malignant group. Fluid, serum VEGF levels, and the ratio of fluid/serum VEGF level were studied to evaluate the fluid/serum VEGF ratio in all groups.ResultsTwenty cases with mesothelioma, 44 cases with other malignancies, and 20 cases with benign aetiologies were included in this study. No statistically significant difference was found according to serum VEGF levels for all groups, (group 1: 437 ±324 pg/ml, group 2: 354 ±223 pg/ml, group 3: 373 ±217 pg/ml, p = 0.836), while fluid VEGF levels showed a statistically significant difference (group 1: 3359 ±700 pg/ml, group 2: 2175 ±435 pg/ml, group 3: 1092 ±435 pg/ml, p = 0.041). The ratio of fluid to serum VEGF levels showed a difference, at the significance limit, between the malignant (group 1 and group 2) and benign (group 3) groups (8.83 ±1.29 vs. 4.57 ±1.07, p = 0.059) but showed a statistically significant difference between the mesothelioma and benign groups (12.11 ±1.68 vs. 4.57 ±1.07, p = 0.044).ConclusionsThe VEGF fluid/serum ratio may be an applicable parameter in the differential diagnosis of malignant fluids, especially MPM.
<b><i>Introduction:</i></b> In the adjuvant treatment of low-risk stage III colon cancer treated surgically, 3 months of CAPOX followed by 3 months of capecitabine is not a common clinical practice. Since there are no data on this practice in the literature, we have no idea how often it is used. However, it should be noted that this application is used in some centers due to the cumulative neurotoxicity of oxaliplatin but there are insufficient data in the literature on its efficacy. <b><i>Methods:</i></b> The data of patients with colon cancer treated surgically who were followed up in 12 different oncology centers in Turkey between November 2004 and June 2022 were analyzed retrospectively. <b><i>Results:</i></b> The study included 194 patients. The treatment arms were as follows: 3 months of CAPOX followed by 3 months of capecitabine = arm A and CAPOX/FOLFOX (6 months) = arm B. There were 78 patients (40.2%) in arm A and 116 patients (59.8%) in arm B. The median age and sex distribution were similar between the treatment arms. The median follow-up period of all patients was 34.4 months (95% confidence interval, 29.1–39.7). When arm A was compared with arm B, 3-year disease-free survival (DFS) was 75.3% versus 88.4% and 5-year DFS was 75.3% versus 82.8%, respectively. There were similar DFS outcomes between the treatment arms (<i>p</i> = 0.09). Rates of any grade of neuropathy were numerically lower in arm A, but the difference between the treatment arms was not statistically significant (51.3% vs. 56.9%; <i>p</i> = 0.44). The frequency of neutropenia was similar between the treatment arms. <b><i>Conclusion:</i></b> In this study, the efficacy and safety of the 3 months of CAPOX followed by 3 months of capecitabine chemotherapy regimen in the adjuvant treatment of low-risk stage III colon cancer treated surgically were proven. This result may also support the discontinuation of oxaliplatin at 3 months while continuing fluoropyrimidines, which is a common clinical practice but lacks sufficient data.
Amaç: Apendiks kanseri (AC), çok nadir görülmektedir. Çoğu hasta akut apandisit nedeniyle opere olduktan sonra veya çekilen bilgisayarlı tomografi sırasında tesadüfen saptanan abdominal kitle nedeniyle tanı almaktadır. Bu çalışmanın amacı, primer apendiks malign tümörlerinin klinik prezantasyonuna göre hastaların tümör histolojik özelliklerini ve hastalara uygulanan tedavi modalitelerini araştırmaktır. Yöntem: Şubat 2012 ile Kasım 2021 tarihleri arasında XXX Üniversitesi ile XXX Eğitim ve Araştırma Hastanesi’ne başvuran ve primer AC tanısı alan 29 hastanın verileri retrospektif olarak incelendi. Hastalar başvuru klinik prezantasyonlarına göre; akut apandisit ve apandisit-dışı klinik şikayetleri ile tanı alan hastalar şeklinde iki gruba ayrıldı. Bulgular: Çalışmamıza toplam 29 hasta alındı. Tüm hastaların medyan yaşı 58 (25-76, min-max) yıldı. Hastaların 19’u (%65,5) kadın hastalardan oluşmaktaydı. Akut apandisit kliniği ile başvuran 11 (%37,9) hasta, apandisit-dışı klinik ile başvuran 18 (%62,1) hasta bulunmaktaydı. Akut apandisit kliniği ile prezante olan grupta iki hasta (%18,2) apandisit-dışı klinik ile prezante olan grupta ise 11 (%61,1) hasta evre-IV olarak tanı almıştı. Sonuç: Çalışmamızda akut apandisit kliniği sonrası tanı konulan apendiks kanserlerinin daha erken evrelerde tanı aldıklarını, daha düşük psödomiksoma peritonei (PMP) oranlarının olduğunu tespit ettik. Akut apandisit kliniği ile tanı konulan grupta hayatını kaybeden hastamız bulunmamaktaydı. Bu da genel sağkalımın bu hasta grubunda daha iyi olacağını düşündürmektedir. Akut apandisit ile prezante olanların daha erken evrede olması göz önüne alınınca sağkalım farklılıkları buradan kaynaklanıyor olabilir.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.